Listen

Press releases

Receive e-mail alerts

Internal link ProQR Announces Extraordinary General Meeting of Shareholders
December 27, 2017 at 12:00 PM UTC
Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
November 29, 2017 at 12:00 PM UTC
Internal link ProQR to Present at the Annual Piper Jaffray Healthcare Conference
November 21, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2017
November 20, 2017 at 12:00 PM UTC
Internal link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
November 14, 2017 at 12:44 PM UTC
Internal link ProQR Announces Proposed Public Offering of Ordinary Shares
November 13, 2017 at 09:01 PM UTC
Internal link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
November 13, 2017 at 12:00 PM UTC
Internal link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
November 09, 2017 at 12:00 PM UTC
Internal link ProQR to Present at EuroTIDES Conference
October 31, 2017 at 11:00 AM UTC
Internal link ProQR Announces Management Change and Key Promotions
October 26, 2017 at 11:00 AM UTC
Internal link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
October 24, 2017 at 11:00 AM UTC
Internal link ProQR to Present at the Chardan Inaugural Gene Therapy Conference
October 06, 2017 at 11:00 AM UTC
Internal link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
September 25, 2017 at 08:00 PM UTC
Internal link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
September 21, 2017 at 11:05 AM UTC
Internal link ProQR to Present at Two Investor Conferences in September
September 21, 2017 at 11:00 AM UTC
Internal link ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
September 19, 2017 at 11:00 AM UTC
Internal link ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
September 12, 2017 at 11:00 AM UTC
Internal link ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
September 05, 2017 at 11:00 AM UTC
Internal link ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
August 29, 2017 at 11:00 AM UTC
Internal link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
August 28, 2017 at 11:00 AM UTC
Internal link ProQR Announces Results for the Second Quarter of 2017
August 16, 2017 at 11:00 AM UTC
Internal link ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
July 05, 2017 at 11:00 AM UTC
Internal link ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
June 15, 2017 at 11:04 AM UTC
Internal link ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
June 13, 2017 at 11:00 AM UTC
Internal link ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
June 08, 2017 at 01:03 PM UTC

Press releases

Internal link ProQR Announces Extraordinary General Meeting of Shareholders

Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Internal link ProQR to Present at the Annual Piper Jaffray Healthcare Conference

Internal link ProQR Announces Results for the Third Quarter of 2017

Internal link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

Internal link ProQR Announces Proposed Public Offering of Ordinary Shares

Internal link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Internal link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board

Internal link ProQR to Present at EuroTIDES Conference

Internal link ProQR Announces Management Change and Key Promotions

Internal link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

Internal link ProQR to Present at the Chardan Inaugural Gene Therapy Conference

Internal link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

Internal link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology

Internal link ProQR to Present at Two Investor Conferences in September

Internal link ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences

Internal link ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics

Internal link ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

Internal link ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial

Internal link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong

Internal link ProQR Announces Results for the Second Quarter of 2017

Internal link ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

Internal link ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology

Internal link ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference

Internal link ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial